TICAM1 Antikörper (C-Term)

Produktnummer ABIN3029186

Der Kaninchen Polyklonal Anti-TICAM1-Antikörper wurde für WB validiert. Er ist geeignet, TICAM1 in Proben von Maus zu detektieren.

Kurzübersicht für TICAM1 Antikörper (C-Term) (ABIN3029186)

Target: TICAM1 (Toll-Like Receptor Adaptor Molecule 1 (TICAM1))

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TICAM1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-TICAM1 Antikörper

Bindungsspezifität: C-Term

Aufreinigung: Antigen affinity

Immunogen: An amino acid sequence from the C-terminus of mouse TRIF (NNHMWGHTGAQSSDDK) was used as the immunogen for this TRIF antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: The stated application concentrations are suggested starting amounts. Titration of the TRIF antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: -20 °C

Informationen zur Lagerung: After reconstitution, the TRIF antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Details zu TICAM1

Target: TICAM1 (Toll-Like Receptor Adaptor Molecule 1 (TICAM1))

Andere Bezeichnung: TRIF

Hintergrund: TICAM1 (TIR domain-containing adaptor molecule 1), also known as TRIF, is an adapter in responding to activation of toll-like receptors(TLRs). It mediates the rather delayed cascade of two TLR-associated signaling cascades, where the other one is dependent upon a MyD88 adapter. By genomic sequence analysis, Oshiumi et al.(2003) mapped the TICAM1 gene to chromosome 19p13.3. By coimmunoprecipitation analysis, Oshiumi et al.(2003) showed that TICAM1 interacts specifically with TLR3, but not with other TLRs. Functional analysis showed that the association of TLR3 and TICAM1 mediates dsRNA activation of IFNB, through either NFKB, AP1, or IRF3. TICAM1 activation of NFKB was found to occur predominantly through IRAK1 rather than IRAK2 . Small interfering(si)RNA blockage of TICAM1, just upstream of the TIR domain, reduced IFNB production in response to dsRNA.

UniProt: Q80UF7

Pathways: TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Toll-Like Receptors Cascades